141 results about "Bicyclo Compounds" patented technology

The present application provides bicyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.

The invention belongs to the field of medicines, and relates to a substituted nitrogen-containing bicyclic compound and application thereof. Specifically, the invention relates to a novel substituted nitrogen-containing bicyclic compound and a pharmaceutical composition containing the compound, the novel substituted nitrogen-containing bicyclic compound can be used for inhibiting PARP1, and the PARP1 selectivity of the novel substituted nitrogen-containing bicyclic compound is obviously higher than that of other PARP subtypes. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preparation of drugs for treating PARP1-mediated diseases, especially cancers.

The present application provides bicyclic compounds of formula (I), formula (II), and formula (III), and pharmaceutically acceptable salts thereof, that are degraders of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The present invention discloses benzobicyclic compounds, preparation methods and applications thereof. Specifically, the present invention discloses a compound having formula (X) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,

The present application provides bicyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.

The present invention relates to a cyclic peptide having the specific formula (I): X1 X2 X3 X4 CX6 X7 X8 PX10 X11 X12 X13 CX15 X16 X17 P (SEQ ID NO: 1) (I) wherein X1 to X17 have various meanings, X1 and D-Pro at position 18 are linked by a peptide bond; the cyclic peptide can be used as an antibacterial agent. The invention also relates to specific bicyclic compounds in which the cysteines in position 5 and 14 are cross-linked by a disulfide bond. The invention also relates to pharmaceutical compositions comprising said peptides and to medical uses of said peptides or compositions comprising them.

The present invention relates to bicyclic compounds. These bicyclic compounds are useful as TEAD binders and / or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and / or treatment of cancer and other severe disorders and diseases.

The invention belongs to the field of medicinal chemistry, and relates to a fused bicyclic compound, in particular to a compound shown in a formula (II), a stereoisomer or pharmaceutically acceptable salt of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound in treating diseases.

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and / or treating glaucoma etc.

This invention provides substituted fused bicyclic compounds as kinase inhibitors and their applications, said substituted fused bicyclic compounds having the structure shown in Formula IIc, wherein R0, A1, A2, B1-B3, D1-D3, R7, and R8 are as defined herein. Compounds of Formula IIc are NUAK1 / 2 inhibitors. Therefore, the compounds of this invention can be used for the treatment and prevention of NUAK1 / 2-mediated diseases, disorders, and conditions, such as cancer, and for the preparation of medicaments for the treatment and prevention of NUAK1 / 2-mediated diseases, disorders, and conditions. (IIc)

A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and / or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

Provided herein are compounds and compositions thereof for modulating hepatocyte growth factor. In some embodiments, the compounds and compositions are provided for the treatment of diseases, including neurological disorders.

The present invention relates to a series of novel heterobicyclic amide derivatives as EP4 receptor antagonists useful in the treatment of diseases or conditions mediated by the action of PGE2 on the EP4 receptor, such as pain, inflammatory diseases and cancer. The scope of the invention also includes pharmaceutical compositions containing such compounds and methods of using these compounds to treat subjects suffering from a condition mediated by the effect of PGE2 on the EP4 receptor.

Compounds of formula (I) or pharmaceutically acceptable salts thereof are described, wherein the substituents are as defined herein. Pharmaceutical compositions containing the compounds and methods of using them are also described. [Formula 1] JPEG2022550641000139.jpg4051

The present invention provides fused bicyclic compounds of formula (I), which are therapeutically useful as SMARCA2 and / or SMARCA4 degraders. These compounds are useful in the treatment and / or delaying progression of disease or disorder dependent upon SMARCA2 and / or SMARCA4 in a subject. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.

Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.

The present application relates to the field of pharmaceutical chemistry, and relates to a fused bicyclic compound and a use thereof, and in particular to a fused bicyclic compound, a preparation method for the compound, a pharmaceutical composition containing the compound, and a use of the compound in the treatment of diseases. The structure of the fused bicyclic compound is represented by formula (I).

The invention provides an electrolyte, a battery, a battery pack and electric equipment. The electrolyte comprises a first additive and a second additive, wherein the first additive is a bicyclic compound, each cyclic group of the bicyclic compound comprises a sulfur-containing functional group, and the second additive comprises a silane group. According to the design of the electrolyte, the first additive and the second additive are introduced, and under the synergistic cooperation of the first additive and the second additive, the battery impedance is reduced, and the cycle life of the battery is prolonged.

The present invention belongs to the field of extraction and separation technology of traditional Chinese medicine, and relates to an azabicyclic compound in purslane, an extraction and separation method, and an application thereof. The new compound has a molecular formula of C6H7NO3 and is named 4-ethyl-3-oxa-1-azabicyclo[2.1.1]hexane-2,5-dione according to its structure. A method for extracting and separating the new compound is also provided, which sequentially uses ethanol reflux extraction, ODS column chromatography, dextran gel chromatography, and high-performance liquid chromatography for separation, purification, and preparation. Its structure is determined to be a new compound using mass spectrometry, hydrogen spectrum, carbon spectrum, and two-dimensional nuclear magnetic spectrum analysis methods, and it has anti-inflammatory activity. The new compound of the present invention and its salts or derivatives can be used as raw materials for drug development and pharmacological activity research.

Formula (I) (in the formula, rings A, W, X, Y, L 1 , R 1 , R 3 and R 4 Compounds of Formula (I), and pharmaceutically acceptable salts thereof, are useful for treating or preventing cancer or immune-related diseases or conditions. Also described are pharmaceutical compositions of the compounds of Formula (I), and methods of using such compounds and compositions.

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N‑oxides, and salts thereof, wherein L, R1, m, R2, R3, and R4, are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling and combating an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the disclosure.

The present invention relates to a crystalline form of Compound 1, a pharmaceutical composition comprising said crystalline form, and the use of said pharmaceutical composition in the treatment of disease. The invention also relates to a preparation method of the compound 1 and the crystal form thereof.

Disclosed is a process for preparing asymmetrically substituted bicyclic compound of formula (III) or (IV) from a compound of formula (I) by pairing a compound of formula (II) with a carbene ligated transition-metal catalyst or a precursor in the presence of a hydride source, wherein the structure of the compound of formula (II) is used as one of the key factors that can alter the selectivity of (III) and (IV) under a given condition.

The present disclosure includes bridged bicyclic compounds and other non-flat organic molecules that have the ability to solvate lithium salts in higher concentrations without significant changes to the electrolyte viscosity which assists in improving the fast charge capability of lithium-ion cells. Using non-flat polar molecules may enable higher solubility of the salts while minimizing viscosity changes to the electrolyte. In some embodiments, the fused bicyclic compound is 7-oxabicyclo[2.2.1]heptane-2-carbonitrile (BHCN).

Bicyclic nitrogen-containing compounds of Formula (I), pharmaceutical compositions comprising these compounds, and their use in the treatment of bacterial infections are described. (see Formula).